Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Danielle Rogner; Tilo Biedermann; Felix Lauffer

doi:10.2340/actadv.v102.1088

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Danielle Rogner, Tilo Biedermann, Felix Lauffer

Medicine and Health

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English
Article number	adv00677
Journal	Acta Dermato-Venereologica
Volume	102
DOIs	https://doi.org/10.2340/actadv.v102.1088
State	Published - 2022

Keywords

Baricitinib
JAK-inhibition
atopic dermatitis

Access to Document

10.2340/actadv.v102.1088

Cite this

@article{480614427fbb4d77af294c611ef9f011,

title = "Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience",

keywords = "Baricitinib, JAK-inhibition, atopic dermatitis",

author = "Danielle Rogner and Tilo Biedermann and Felix Lauffer",

note = "Funding Information: is member of advisory boards and/or speaker for Novartis, Abb-vie, Lilly, Janssen, UCB, Amgen, Almirall, Sanofi, LEO Pharma and Roche, not related to this study. TB gave advice to or got an honorarium for talks or research grant from the following companies: Alk-Abell{\'o}, Celgene-BMS, Galderma, GlaxoSmithKline, Leo Pharma, Lilly Deutschland GmbH, Mylan, Novartis, Phadia-Thermo Fisher, Sanofi-Genzyme and Regeneron.",

year = "2022",

doi = "10.2340/actadv.v102.1088",

language = "English",

volume = "102",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden AB",

}

TY - JOUR

T1 - Treatment of Atopic Dermatitis with Baricitinib

T2 - First Real-life Experience

AU - Rogner, Danielle

AU - Biedermann, Tilo

AU - Lauffer, Felix

N1 - Funding Information: is member of advisory boards and/or speaker for Novartis, Abb-vie, Lilly, Janssen, UCB, Amgen, Almirall, Sanofi, LEO Pharma and Roche, not related to this study. TB gave advice to or got an honorarium for talks or research grant from the following companies: Alk-Abelló, Celgene-BMS, Galderma, GlaxoSmithKline, Leo Pharma, Lilly Deutschland GmbH, Mylan, Novartis, Phadia-Thermo Fisher, Sanofi-Genzyme and Regeneron.

PY - 2022

Y1 - 2022

KW - Baricitinib

KW - JAK-inhibition

KW - atopic dermatitis

UR - http://www.scopus.com/inward/record.url?scp=85127348297&partnerID=8YFLogxK

U2 - 10.2340/actadv.v102.1088

DO - 10.2340/actadv.v102.1088

M3 - Article

C2 - 35083493

AN - SCOPUS:85127348297

SN - 0001-5555

VL - 102

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

M1 - adv00677

ER -

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Keywords

Access to Document

Other files and links

Cite this